Amag Pharmaceuticals (AMAG) 27.02 $AMAG How These

New Post Public Reply Private Reply Replies (0) Message Board

Aug 2, 2016 at 1:23 AM

Amag Pharmaceuticals (AMAG) 27.02 $AMAG

How These Healthcare Stocks are Performing? -- AMAG Pharma, IDEXX Laboratories, Neogenomics, and ICON
PR Newswire - Fri Jul 29, 7:50AM CDT
The Healthcare sector remains one of the most stable industries in the market, unfazed by economic conditions and uncertainties. While the industry faces issues with cost pressures, ransomware risks, and existing policies, several companies remain unscathed and continue to impress with significant returns. Stocks to evaluate today on Stock-Callers.com are AMAG Pharmaceuticals Inc. (NASDAQ: AMAG), IDEXX Laboratories Inc. (NASDAQ: IDXX), Neogenomics Inc. (NASDAQ: NEO), and ICON PLC (NASDAQ: ICLR). Learn more about these stocks by accessing their free notes at:
NEO: 8.52 (-0.20), AMAG: 27.02 (+0.49), IDXX: 93.51 (-0.28), ICLR: 76.97 (-0.70)

AMAG Pharmaceuticals Shares Up 17.6% Since SmarTrend's Buy Recommendation (AMAG)
Comtex SmarTrend(R) - Wed Jul 27, 1:06AM CDT
SmarTrend identified an Uptrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on May 31st, 2016 at $21.22. In approximately 2 months, AMAG Pharmaceuticals has returned 17.58% as of today's recent price of $24.95.
AMAG: 27.02 (+0.49)

AMAG Pharmaceuticals Shares Up 20.3% Since SmarTrend's Buy Recommendation (AMAG)
Comtex SmarTrend(R) - Tue Jul 12, 1:27AM CDT
SmarTrend identified an Uptrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on May 31st, 2016 at $21.22. In approximately 1 month, AMAG Pharmaceuticals has returned 20.26% as of today's recent price of $25.52.
AMAG: 27.02 (+0.49)

Should You Get Rid of AMAG Pharmaceuticals (AMAG) Now?
Zacks Equity Research - Zacks Investment Research - Wed May 25, 7:54AM CDT
AMAG Pharmaceuticals has witnessed a significant price decline in the past four weeks and negative estimate revisions, making it time for investors to sell it off.
ANIP: 61.06 (+0.46), AMAG: 27.02 (+0.49)

AMAG Pharmaceuticals to Present at Upcoming Investor Conferences
GlobeNewswire - Wed May 25, 7:08AM CDT
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that company management will discuss AMAG's business and financial outlook, strategy and growth prospects at the following investor conferences taking place in June 2016.
AMAG: 27.02 (+0.49)

Why Investors Still See Value in Alkermes, AMAG Pharmaceuticals, IDEXX Laboratories and Atossa Genetics?
PR Newswire - Thu May 19, 7:50AM CDT
The equities market is never short of surprises, and one sector that is always abounding of surprises is without doubt the Healthcare space. ActiveWallSt.com has uncovered four stocks in the Healthcare sector ahead of today's trading session: Alkermes PLC (NASDAQ: ALKS), AMAG Pharmaceuticals Inc. (NASDAQ: AMAG), IDEXX Laboratories Inc. (NASDAQ: IDXX), and Atossa Genetics Inc. (NASDAQ: ATOS). Sign up for your complimentary alerts at:
ATOS: 0.27 (+0.02), AMAG: 27.02 (+0.49), IDXX: 93.51 (-0.28), ALKS: 49.56 (-0.34)

New Strong Sell Stocks for May 19th
Swarup Gupta - Zacks Investment Research - Thu May 19, 7:45AM CDT
5 fresh stock additions to the Zacks Rank #5 (Strong Sell) List for Thursday
UEPS: 10.14 (-0.20), PLM: 0.74 (-0.01), MTGE: 16.47 (+0.11), WY: 32.75 (+0.03), AMAG: 27.02 (+0.49)

AMAG Pharmaceuticals Announces 2016 Analyst Day
GlobeNewswire - Thu May 19, 7:00AM CDT
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG), a specialty pharmaceutical company with a diverse portfolio of products in the areas of maternal health, anemia management and cancer supportive care, today announced that it will host an Analyst Day in New York City on Wednesday, June 1, 2016. The event will start at 8:30 a.m. and conclude at approximately 12:00 p.m. ET.
AMAG: 27.02 (+0.49)

AMAG Pharmaceuticals Has Returned 19.3% Since SmarTrend Recommendation (AMAG)
Comtex SmarTrend(R) - Wed May 18, 1:21AM CDT
SmarTrend identified a Downtrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on May 3rd, 2016 at $23.23. In approximately 2 weeks, AMAG Pharmaceuticals has returned 19.29% as of today's recent price of $18.75.
AMAG: 27.02 (+0.49)

Downgrade Alert for AMAG Pharmaceuticals (AMAG)
Comtex SmarTrend(R) - Thu May 05, 3:36AM CDT
AMAG Pharmaceuticals (NASDAQ:AMAG) was downgraded from Outperform to Market Perform at Raymond James today. The stock closed yesterday at $19.55 on volume of 4.3 million shares, above average daily volume of 1.0 million. AMAG Pharmaceuticals share prices have moved between a 52-week high of $77.73 and a 52-week low of $20.22 and closed yesterday at -3% above that low price at $19.55 per share. Over the past week, the 200-day moving average (MA) has gone down 2.2% while the 50-day MA has declined 0.7%.
AMAG: 27.02 (+0.49)

AMAG Pharmaceuticals Reports First Quarter 2016 Financial Results
GlobeNewswire - Tue May 03, 6:00AM CDT
-- First quarter 2016 non-GAAP product revenue increased 52% to $117.6 million
AMAG: 27.02 (+0.49)

AMAG Pharmaceuticals to Participate in the Deutsche Bank 41st Annual Healthcare Conference
GlobeNewswire - Wed Apr 27, 7:02AM CDT
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that management will participate in an analyst-led fireside chat at the Deutsche Bank 41 Annual Healthcare Conference on Wednesday, May 4, 2016 at 8:40 a.m. ET in Boston.
DB: 13.07 (-0.37), AMAG: 27.02 (+0.49)

AMAG Pharmaceuticals to Host Conference Call on May 3, 2016 at 8:00 a.m. ET to Discuss Financial Results for the First Quarter Ended March 31, 2016
GlobeNewswire - Thu Apr 21, 7:03AM CDT
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced it will report unaudited consolidated financial results for the first quarter ended March 31, 2016 before the U.S. financial markets open on Tuesday, May 3, 2016. The announcement will be followed by a conference call and webcast with slides at 8:00 a.m. ET, during which management will provide an update on recent developments and discuss the company's first quarter 2016 financial and operating results.
AMAG: 27.02 (+0.49)

Gilead Presents Multiple HCV and HBV Data at Liver Congress
Zacks Equity Research - Zacks Investment Research - Mon Apr 18, 12:59PM CDT
Gilead Sciences (GILD) presented results from several phase II and phase III studies for the treatment of HCV and HBV infection at The International Liver Congress.
EBS: 30.97 (-2.42), GILD: 80.46 (+0.99), AMAG: 27.02 (+0.49), ANIK: 50.64 (+0.72)

Synta Stock Up on Merger Deal with Madrigal Pharmaceuticals
Zacks Equity Research - Zacks Investment Research - Fri Apr 15, 10:30AM CDT
Synta (SNTA) announced all-stock merger transaction with Madrigal Pharmaceuticals to create a company focused on cardiovascular-metabolic diseases and NASH.
SNTA: 0.34 (+0.07), EBS: 30.97 (-2.42), ICPT: 169.72 (-3.31), AMAG: 27.02 (+0.49)

Intrexon (XON) Gains Following Deals with Two Startups
Zacks Equity Research - Zacks Investment Research - Thu Apr 14, 2:40PM CDT
Intrexon's (XON) shares gained after the company announced exclusive channel collaborations with a couple of Harvest Intrexon Enterprise Fund-backed startups.
EBS: 30.97 (-2.42), FCSC: 1.02 (-0.07), XON: 27.38 (+2.05), AMAG: 27.02 (+0.49)

Merck Offers Positive Data from Comparative Trial on Zepatier
Zacks Equity Research - Zacks Investment Research - Thu Apr 14, 10:20AM CDT
Merck (MRK) announced results from a phase III study which compared Zepatier to a regimen of Gilead's Sovaldi plus peginterferon and ribavirin.
EBS: 30.97 (-2.42), GILD: 80.46 (+0.99), MRK: 58.66 (unch), AMAG: 27.02 (+0.49)

Arena (ARNA) Gains, Pain Drug Positive in Early Stage Study
Zacks Equity Research - Zacks Investment Research - Wed Apr 13, 12:00PM CDT
Arena (ARNA) announced favorable results from a phase Ib study on its pain candidate, APD371.
EBS: 30.97 (-2.42), AMAG: 27.02 (+0.49), ANIK: 50.64 (+0.72), ARNA: 1.68 (+0.01)

Repros Reveals Positive Data on Proellex for Uterine Fibroids
Zacks Equity Research - Zacks Investment Research - Wed Apr 13, 11:30AM CDT
Repros (RPRX) reported positive data from a phase IIb study on Proellex (vaginal administration) for the treatment of women suffering from uterine fibroids.
EBS: 30.97 (-2.42), RPRX: 2.06 (-0.06), AMAG: 27.02 (+0.49), ANIK: 50.64 (+0.72)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Dr. David Lifschutz Honored for Psychiatry Innovation

Recognizing a Legacy in Mental Wellness Under the glare of recognition's spotlight, Dr. David H. Lifschutz steps into an exclusive circle of elite professionals. He's been acknowledged as a Pinnacle Lifetime Member by The Inner Circle for his remarkable contributions to psychiatry and mental health care. This ain't just any pat on the back. It's a badge of honor stitched...

Microplastics Webinar: Navigating Complex Regulations

Buckle up, folks. The plastics debate is where regulatory battles and environmental concerns collide, and big changes are on the horizon. Let's talk about Bergeson & Campbell's latest shindig: "Plastics and Policy: Microplastics, EPR, and Other Emerging Trends"—a free-to-join webinar aiming to lift the lid on what's brewing beneath the surface of regulatory waters. The...

NSF Backs New Space Projects: Cooling & Drug Delivery

You know, every time we think we're at the edge of current science, space reminds us how little we actually know. From the International Space Station up there in low Earth orbit, fresh experiments are kicking off to change what we understand about electronics cooling and drug delivery. It's a classic scenario of reaching for the stars to help us out back here on Earth....

Amy Wilson Joins ITSA Board: A New Era for UBI?

An Unexpected Turn in the UBI Movement In a world where tech and economic security must dance together, minding the steps is crucial. And this time, Amy Wilson's got her dancing shoes on. On September 24, 2026, the Income To Support All (ITSA) Foundation made some waves by adding Wilson to its board of directors, a move showing they're more serious than ever about...

NORD Honors Innovators Shaping Rare Disease Treatment

Saluting the Trailblazers in Rare Disease Space Alright, let's cut to it. In a world flooded with more rare diseases than most of us can count, about 10,000 of them, only a measly 5% have any kind of approved treatment. The National Organization for Rare Disorders (NORD) is out here celebrating the folks who dare to change that bleak outlook. With the 2026 Rare Impact...

Brands Must Choose: Cost or Value Leadership?

Navigating the Business Jungle: Strategic Choices Unveiled If you've ever found yourself tangled in a web of corporate doublespeak, then you'll nod along with this: all those lofty brand management strategies often boil down to a fight over dollars or dizzying customer satisfaction. What's the winning play? According to Info-Tech Research Group, it's about firmly standing...

Spotlight on AI-Powered Smart Homes for 2027

Gearing Up for the Connected Home Revolution Ah, the thrill of peering into the future of smart homes! That's what's cookin' as Parks Associates gears up for its annual CONNECTIONS™ Conference slated for May 4-6, 2027. This isn't just another routine pow-wow. Nope, this get-together is about seeing who's leading the pack in transforming our everyday spaces into...

Retirement Security Faces Global Headwinds in 2026

Grappling with an Uncertain Retirement Future Welcome to the 2026 Global Retirement Index (GRI), where it seems we're all being told to brace for a rough retirement ride. This year's results, crafted by Natixis Investment Managers and their pals at CoreData Research, spotlight just how shaky the ground has gotten. The core troublemakers? Aging populations, whopping public...

CATL Opens Europe's Largest Battery Service Hub

A New Era for EV Batteries in Norway Stepping into Oslo's tech realm, CATL's grand opening is not just another corporate ribbon-cutting spree. It's a big splash in Europe's battery pool, boasting the largest NING SERVICE center outside of Asia. Here we are, folks, at the crossroads where the EV market meets the nitty-gritty of practical service. Norway's Electric...

Stravito's MCP Server Revolutionizes AI in Business

We're seeing another big swing in how enterprises weave AI into the fabric of decision-making. Stravito, an enterprise customer intelligence platform, launched its Model Context Protocol (MCP) Server. This thing brings company-owned research right into the gizmos teams already use. Now, businesses aren't left groping in the dark figuring out their next moves—pretty...